These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22205191)

  • 1. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.
    Fujimura N; Noma K; Hata T; Soga J; Hidaka T; Idei N; Fujii Y; Mikami S; Maruhashi T; Iwamoto Y; Kihara Y; Chayama K; Kato H; Liao JK; Higashi Y;
    Clin Pharmacol Ther; 2012 Feb; 91(2):289-97. PubMed ID: 22205191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium channel blocker and Rho-associated kinase activity in patients with hypertension.
    Hata T; Soga J; Hidaka T; Idei N; Fujii Y; Fujimura N; Mikami S; Maruhashi T; Kihara Y; Chayama K; Kato H; Noma K; Liao JK; Higashi Y;
    J Hypertens; 2011 Feb; 29(2):373-9. PubMed ID: 21063203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study.
    Kishimoto S; Oki K; Maruhashi T; Kajikawa M; Matsui S; Hashimoto H; Takaeko Y; Kihara Y; Chayama K; Goto C; Aibara Y; Yusoff FM; Nakashima A; Noma K; Liao JK; Higashi Y
    J Hypertens; 2019 May; 37(5):1083-1095. PubMed ID: 30418321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension.
    Oshima T; Ozono R; Yano Y; Higashi Y; Teragawa H; Miho N; Ishida T; Ishida M; Yoshizumi M; Kambe M
    Hypertens Res; 2005 Nov; 28(11):889-94. PubMed ID: 16555577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.
    Kobayashi N; Fukushima H; Takeshima H; Koguchi W; Mamada Y; Hirata H; Machida Y; Suzuki N; Yokotsuka F; Tabei K; Kobayashi E; Fukuda N; Ishimitsu T
    Am J Hypertens; 2010 Sep; 23(9):1007-13. PubMed ID: 20431528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplerenone: a selective aldosterone blocker.
    Stier CT
    Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
    Minas JN; Thorwald MA; Conte D; Vázquez-Medina JP; Nishiyama A; Ortiz RM
    Clin Exp Pharmacol Physiol; 2015 Nov; 42(11):1178-88. PubMed ID: 26234762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor antagonists and endothelial function.
    Maron BA; Leopold JA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of Adrenalectomy and Eplerenone on Vascular Function in Patients with Aldosterone-producing Adenoma.
    Kishimoto S; Oki K; Maruhashi T; Kajikawa M; Hashimoto H; Takaeko Y; Harada T; Yamaji T; Han Y; Kihara Y; Chayama K; Goto C; Yusoff FM; Nakashima A; Higashi Y
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32818224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.
    Hwang MH; Yoo JK; Luttrell M; Kim HK; Meade TH; English M; Talcott S; Jaffe IZ; Christou DD
    Exp Gerontol; 2016 Jan; 73():86-94. PubMed ID: 26639352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway.
    Kobayashi N; Hara K; Tojo A; Onozato ML; Honda T; Yoshida K; Mita S; Nakano S; Tsubokou Y; Matsuoka H
    Hypertension; 2005 Apr; 45(4):538-44. PubMed ID: 15710785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension.
    Quaschning T; Ruschitzka F; Shaw S; Lüscher TF
    Hypertension; 2001 Feb; 37(2 Pt 2):801-5. PubMed ID: 11230376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
    Sato A; Fukuda S
    J Hum Hypertens; 2010 Jun; 24(6):387-94. PubMed ID: 19865106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
    Savoia C; Touyz RM; Amiri F; Schiffrin EL
    Hypertension; 2008 Feb; 51(2):432-9. PubMed ID: 18195160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
    Mihailidou AS; Mardini M; Funder JW; Raison M
    Hypertension; 2002 Aug; 40(2):124-9. PubMed ID: 12154101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.